Related Experiment Video
Updated: Aug 2, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Emerging evidence and treatment paradigm of non-small cell lung cancer
Si-Yang Maggie Liu1, Mei-Mei Zheng2, Yi Pan2
1Department of Hematology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Abstract:
Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice.
Insights
Biomarker-driven therapy and immune checkpoint inhibitors are revolutionizing non-small cell lung cancer (NSCLC) treatment. This review summarizes evolving strategies and proposes future clinical directions for NSCLC care.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) treatment landscape is rapidly evolving.
- Advances in understanding tumor biology and immune interactions drive new therapeutic strategies.
- Personalized medicine is becoming central to NSCLC management.
Purpose of the Study:
- To review emerging targeted therapies and immunotherapies for NSCLC.
- To summarize agents that are shifting the treatment paradigm across all NSCLC stages.
- To propose updated treatment algorithms and identify key clinical challenges.
Main Methods:
- Comprehensive literature review of recent clinical trials and evidence.
- Analysis of biomarker-driven therapies and immune checkpoint inhibitors.
- Synthesis of data to propose clinical management strategies.
Main Results:
- Identification of promising targeted agents and checkpoint inhibitors.
- Demonstration of paradigm shifts in NSCLC treatment across various stages.
- Outline of current evidence-based treatment algorithms.
Conclusions:
- Targeted therapy and immunotherapy have significantly improved NSCLC outcomes.
- Ongoing clinical trials are addressing critical unmet needs in NSCLC.
- Future clinical practice will be shaped by the results of these evolving trials.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...